Roche has the world's most abundant pipeline drug. According to Evaluate Pharma's report, it estimates the net present value of its pipeline drugs to reach $43.4 billion, which is the highest net present value valuation of the drug development pipeline in the pharmaceutical industry. At present, Roche has as many as 141 pipeline drug projects underway, at least 49 in Phase III clinical trials and 13 in new molecular entities, many of which are heavy drugs. Let's take a look at Roche's 10 most promising pipeline drugs.
TOP10, RG6083 olesoxime
The drug was obtained when Roche acquired the French biotech company Trophos for $470 million in January 2015. It belongs to a class of drugs called mitochondrialpore modulators, which have cholesterol-like properties. The structure can play a neuroprotective function. Preclinical studies have found that this drug can effectively promote the function of neurons and maintain the survival of nerve cells. The clinical study of this drug for multiple sclerosis ended in 2009-2011, and the current phase III clinical trial for the treatment of spinal muscular atrophy is underway. Spinal muscular atrophy is a rare hereditary neuromuscular disease most commonly found in children. Phase II clinical trials have shown that olesoxime is effective in maintaining neuromuscular function while reducing complications, and the drug is expected to be available around 2020.
TOP9, Gantenerumab
Gantenerumab is a fully humanized monoclonal antibody that specifically binds to β-amyloid plaques for the treatment of Alzheimer's disease. Whether β-amyloid plaque is the culprit causing Alzheimer's disease has been controversial. Although scientists have been studying for more than 30 years, there is a close relationship between β-amyloid plaque and senile dementia. Drugs have the effect of reducing beta-amyloid plaques, but they do not alleviate the disease progression of Alzheimer's disease, making people doubt this argument. Therefore, Roche has also shelved Gantenerumab, which is in the clinical research stage. Until 2015, Biogen's Aducanumab showed in clinical stage 1b that Aducanumab can reduce amyloid plaques in patients with prodromal or mild Alzheimer's disease, and can delay cognitive function. The decline in function, the results of this study corroborate the current hypothesis that beta amyloid causes Alzheimer's disease, and brings hope to a number of clinical research drugs including Gantenerumab. Therefore, in 2015 Roche restarted the clinical phase III trial of Alzheimer's disease in Gantenerumab, predicting a peak sales of $500 million.
TOP8, Idasanutlin (RG7388)
RG7388 is a so-called second-generation p53-MDM2 inhibitor. Preclinical studies have shown that RG7388 can selectively inhibit the binding of P53 and MDM2 at low nanomolar levels. RG7388 selectively binds to the P53 site on the surface of MDM2, p53 Isolation from MDM2 results in activation of P53 and activation of the apoptosis program, thereby killing cancer cells. Currently, Roche is undergoing a phase III clinical study of acute myeloid leukemia (acutemyeloid leukemia). Potential indications for RG7388 include chronic lymphocytic leukemia, acute lymphocytic leukemia, acute myeloid leukemia, multiple myeloma, melanoma, neuroblastoma, mantle cell lymphoma, etc. These cancers are characterized by the presence of wild-type p53. At the same time, MDM2 is overexpressed. In the academic world, p53 is the target for cancer research. It is not new, but there is no p53-targeted drug listed, indicating that the academic to industrial path is not so good, p53 has no tyrosine kinase. Simple, whether this drug can be successfully listed needs to be observed.
Foam Portable Fire Extinguisher
Foam Portable Fire Extinguisher,Red 9L Portable Foam Fire Extinguisher,9L Red Foam Portable Fire Extinguisher,Red 6L Portable Foam Fire Extinguisher
JIANGSU NEW FIRE FIGHTING TECHNOLOGY CO.,LTD , https://www.newayfire.com